Problems viewing this newsletter? View it in your browser >

Next Webinar: New PrEP data explained

September 22, 2014

Dear Advocates,

Join us on Wednesday, September 24 at 10 AM ET US for a webinar — Results of the iPrEx open-label extension (iPrEx OLE): PrEP uptake, sexual practices and HIV incidence. This call is a great chance to get updated on the latest data — including information that can help debunk fears about disinhibition and bolster the case for oral PrEP as a prevention option.

Our presenter, Dr. Robert Grant, is the principal investigator of the iPrEx and iPrEx OLE PrEP studies (and involved in several others), and has been a leader in the PrEP research and implementation arena for over a decade. He will present on iPrEx OLE including data on PrEP uptake, sexual risk, adherence and more. He will also be on hand to discuss how the data may help inform PrEP use and programming in the “real world”. 
Register here.

Much of the data we’ll be discussing were presented or discussed at AIDS 2014 in Melbourne. Whether you attended or not, you probably have questions about what happened — and what it all meant. This webinar is part of our Research & Reality series, designed to delve into these issues. 

Check out the full schedule below for links to recordings and slides from earlier webinars and registration links for those upcoming!
UPCOMINGResults of the iPrEx open-label extension (iPrEx OLE): PrEP uptake, sexual practices and HIV incidence
Get details on the iPrEx OLE study from principal investigator Robert Grant, who presented the data at AIDS 2014. The first open-label PrEP study to publish results, data from iPrEx OLE begin to answer a number of questions on PrEP use in the “real world”.
September 24, 10–11am ET; register here

Data and Uncertainty: Understanding updates on hormonal contraceptives and HIV
AIDS 2014 featured analyses of data on the potential relationship between hormonal contraceptives and risk of HIV infection. Researchers Charles Morrison (FHI 360), Kristin Wall (Emory University) and Mary Lyn Gaffield (WHO) will discuss the newest findings and guidance.
October 1, 10–11am ET; register here

UNAIDS, Targets and Civil Society 
In Melbourne, UNAIDS launched a new initiative known as “90-90-90”, which lays out new targets for testing, treatment and virologic suppression. Where did these targets come from, what do they mean—and where does prevention fit in? Chris Collins, Chief of the Community Mobilization Division at UNAIDS, will address these questions and more. 
October 8, 10–11am ET; register here [rescheduled from September 10] 

PAST Latest developments in VMMC research and implementation 
Slides: PDF

State of the Art HIV Cure: Where are we now and where are we going?
Animation: Flash, Audio: MP3, Slides: PDF

As always, questions or comments are most welcome, and we look forward to welcoming you on the webinars!



Diaphragm to prevent unintended pregnancy (and maybe someday HIV)A new contraceptive option, the SILCS Diaphragm, was approved by the FDA for marketing in the US last week and work is underway to get it to women in low-income countries. This development is key as it relates to some of the major research questions under consideration in HIV prevention for women.


Forward This IssueDo you know someone who might be interested in receiving this newsletter?
Forward > 

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
Unsubscribe > 

Contact Us T: +1 212 796 6423